Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases

Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not associated with renal complications; however, an accumulating body of evidence suggests that multiple growth factors, cytokines, endothelial damage, and an activated complement system in these patients can induce glomerulopathy, as nearly a third of these patients present with advanced renal disease on diagnosis, which is unlikely to be age or hypertension-related. In this report, we present two cases of patients with MPN/MDS, a 45-year-old male with essential thrombocythemia and a 73-year-old male with polycythemia vera, both of whom developed generalized edema and were referred to our institution from their outpatient nephrologists due to accompanying proteinuria. Renal biopsy of the first patient revealed mesangiocapillary and mesangioproliferative MPN-associated glomerulopathy. In contrast, the second patient was diagnosed with MPN/MDS-associated segmental mesangial proliferative glomerulonephritis and renal vasculature drug toxicity. Both patients were started on treatment - corticosteroid as per consensus.

[1]  C. Sticht,et al.  Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms , 2020, Histopathology.

[2]  S. Koschmieder,et al.  Role of inflammation in the biology of myeloproliferative neoplasms. , 2020, Blood reviews.

[3]  G. Bohra,et al.  Focal segmental glomerulosclerosis in a patient with prefibrotic primary myelofibrosis , 2018, BMJ Case Reports.

[4]  D. Jo,et al.  Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study , 2017, The Korean journal of internal medicine.

[5]  J. Aniort,et al.  Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  G. Barbatelli,et al.  Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era , 2017, Clinical nephrology. Case studies.

[7]  G. Barbatelli,et al.  WITHDRAWN: Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era. , 2017, Clinical nephrology.

[8]  A. Dueck,et al.  Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development , 2015, Mediators of inflammation.

[9]  S. Verstovsek,et al.  Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib , 2015, BMC Nephrology.

[10]  H. Hasselbalch,et al.  Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. , 2014, Leukemia research.

[11]  J. Bay,et al.  [The myeloproliferative neoplasms-related glomerulopathy]. , 2014, La Revue de medecine interne.

[12]  K. Hatta,et al.  Renal biopsy cases in myeloproliferative neoplasms (MPN) , 2013, CEN Case Reports.

[13]  T. Robak,et al.  JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. , 2013, Current Medicinal Chemistry.

[14]  V. D’Agati,et al.  Myeloproliferative neoplasms cause glomerulopathy. , 2011, Kidney international.

[15]  F. Cakalagaoglu,et al.  Focal Segmental Glomerulosclerosis Associated with Idiopathic Myelofibrosis , 2010, Renal failure.

[16]  C. Alpers,et al.  A new look at platelet-derived growth factor in renal disease. , 2008, Journal of the American Society of Nephrology : JASN.

[17]  Nong Zhang,et al.  Aldose reductase regulates TGF‐β1‐induced production of fibronectin and type IV collagen in cultured rat mesangial cells , 2006, Nephrology.

[18]  T. Kondo,et al.  Focal segmental glomerulosclerosis associated with essential thrombocythemia , 2006, Clinical and Experimental Nephrology.

[19]  K. Chan,et al.  Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  M. Martyré TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. , 1995, Leukemia & lymphoma.

[21]  M. Perazella,et al.  Nephrotic syndrome associated with agnogenic myeloid metaplasia. , 1994, American journal of nephrology.

[22]  G. Striker,et al.  Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Gown,et al.  Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Bryckaert,et al.  Increased intraplatelet levels of platelet‐derived growth factor and transforming growth factor‐β in patients with myelofibrosis with myeloid metaplasia , 1991, British journal of haematology.

[25]  E. Ruoslahti,et al.  Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.